NextCure, Inc.
10
3
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
40.0%
4 terminated/withdrawn out of 10 trials
20.0%
-66.6% vs industry average
0%
0 trials in Phase 3/4
400%
4 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Role: lead
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Role: collaborator
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Role: lead
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Role: lead
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Role: collaborator
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Role: lead
All 10 trials loaded